Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 (GLOBE NEWSWIRE) —
Prodrug of oral amyloid beta aggregation modulator demonstrated improved absorption traits, resulting in considerably increased systemic peak drug degree and, in the end, to enough publicity with decrease dosesSuperior PK profile allows considerably decreased oral dosing quantity, supporting this next-generation compound as a promising new oral improvement candidate for Alzheimer’s illness
Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 – Galimedix Therapeutics, Inc. (“Galimedix”), a Section 2 clinical-stage biotechnology firm growing novel oral and topical neuroprotective therapies with the potential to revolutionize the remedy of significant mind and eye ailments, introduced preclinical information showcasing the improved pharmacokinetic (PK) profile of a next-generation amyloid-beta (Aβ) aggregation modulator for Alzheimer’s illness. The poster, entitled, “New oral prodrug of the Aβ aggregation modulator GAL-201 shows significantly improved pharmacokinetic profile”, was introduced on the Worldwide Convention on Alzheimer’s and Parkinson’s Illnesses and associated neurological problems (AD/PD™ 2026: advances in science and remedy), being held in Copenhagen, Denmark, March 17-21, 2026.
“The data presented at AD/PD™ 2026 demonstrate the rapid absorption and significantly higher peak plasma concentrations of this new prodrug compared to the parent compound,” stated Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer of Galimedix. “These characteristics make this prodrug a promising new oral Aβ-targeting development candidate that could offer enhanced efficacy and patient-friendly dosing for the long-term treatment of Alzheimer’s disease.”
Prodrug demonstrates fast and full absorption, enabling decreased oral doses, vital for long-term administration Galimedix has a number of compounds in improvement that neutralize soluble, poisonous types of Aβ early within the aggregation course of, and thereby forestall neurodegeneration. Preclinical research present constant disease-modifying results throughout Alzheimer’s, glaucoma and dry AMD fashions mediated by peak plasma concentrations. Whereas the oral bioavailability in rats was proven to be acceptable, improved bioavailability would cut back oral drug doses, which might be a bonus for sufferers. Thus, Galimedix derived subsequent era molecules with the purpose of enhancing PK properties based mostly on absorption and systemic publicity concerns.
More Read
This superior PK profile allows considerably decreased oral doses, which is especially vital given the necessity for long-term administration for sufferers with Alzheimer’s illness.
The poster will be accessed right here: AD/PD 2026: Galimedix Poster
About Galimedix Therapeutics, Inc. Galimedix is a Section 2 clinical-stage personal firm growing novel oral and topical neuroprotective therapies with the potential to revolutionize the remedy of significant eye and mind ailments. Based by a seasoned and extremely devoted crew of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules provide the hope of adjusting the course of illness the place amyloid beta (Aβ) performs a task, equivalent to in Alzheimer’s illness, dry age-related macular degeneration (AMD) and glaucoma – Galimedix’s preliminary areas of focus. For extra info, go to www.galimedix.com and observe us on LinkedIn.
More Read
20260320_Galimedix_AD-PD 2026
